Furthermore, PD-L1 expression and the efficacy of immunotherapy are influenced by treatment regimens, tumor heterogeneity, and tumor microenvironment, resulting in only a few patients benefiting from it in the long term (5). This evidence concerns the gene CD274 and neoplasm.